CYTOF — Altamira Therapeutics Balance Sheet
0.000.00%
- $0.52m
- $1.31m
Annual balance sheet for Altamira Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | fx Final | fx Final | fx Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 12.7 | 1.08 | 0.017 | 0.734 | 0.999 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.091 | 0.76 | 0.825 | 0.089 | 0.351 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 13.1 | 4.49 | 1.91 | 1.45 | 1.54 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.053 | 0.619 | 0.482 | 0.095 | 0.45 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Total Assets | 23.5 | 21 | 6.82 | 9.14 | 8.65 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 3.42 | 5.33 | 13.9 | 1.06 | 1.16 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 4.55 | 6.72 | 15.8 | 1.47 | 2.09 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 18.9 | 14.3 | -8.99 | 7.68 | 6.57 |
| Total Liabilities & Shareholders' Equity | 23.5 | 21 | 6.82 | 9.14 | 8.65 |
| Total Common Shares Outstanding |